Novel Thrombolytic Drug Based on Thrombin Cleavable Microplasminogen Coupled to a Single‐Chain Antibody Specific for Activated GPIIb/IIIa

BACKGROUND: Thrombolytic therapy for acute thrombosis is limited by life‐threatening side effects such as major bleeding and neurotoxicity. New treatment options with enhanced fibrinolytic potential are therefore required. Here, we report the development of a new thrombolytic molecule that exploits...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonnard, Thomas, Tennant, Zachary, Niego, Be'Eri, Kanojia, Ruchi, Alt, Karen, Jagdale, Shweta, Law, Lok Soon, Rigby, Sheena, Medcalf, Robert Lindsay, Peter, Karlheinz, Hagemeyer, Christoph Eugen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5523756/
https://www.ncbi.nlm.nih.gov/pubmed/28159824
http://dx.doi.org/10.1161/JAHA.116.004535

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5523756/
https://www.ncbi.nlm.nih.gov/pubmed/28159824
http://dx.doi.org/10.1161/JAHA.116.004535

Ejemplares similares